Potential cardioprotective effects of gypenosides: a review on preclinical studies targeting the ROS-mitochondria-lipid axis in atherosclerosis and ischaemia-reperfusion injury
Pharmacological Research - Modern Chinese Medicine · 2026-11 · 100901
DOI: 10.1016/j.prmcm.2026.100901 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacological Research - Modern Chinese Medicine, 2026-11. Verfasst von AbdulRahman Muthanna und 6 weiteren Autor:innen. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science and Technology Council.
Abstract (Originalsprache)
Introduction
Cardiovascular disease remains a leading cause of global morbidity and mortality, driven largely by chronic atherosclerosis and acute myocardial ischaemia–reperfusion (I/R) injury. These processes share a self-amplifying axis linking reactive oxygen species (ROS), mitochondrial dysfunction, and dyslipidaemia. Gypenosides, the dammarane-type saponins of Gynostemma pentaphyllum (Thunb.) Makino (Jiǎogǔlán), engage this axis at several nodes. In traditional Chinese medicine (TCM), the herb replenishes qi, fortifies the spleen, and resolves phlegm, and total gypenosides are formulated as lipid-lowering patent preparations.
Methods
PubMed, Web of Science, Scopus, and Google Scholar were searched from inception to April 2026 (updated October 2026; English only). Original in vitro and in vivo studies reporting cardiovascular, endothelial, mitochondrial, antioxidant, or lipid outcomes were included, together with chemical, pharmacokinetic, toxicological, delivery, and clinical reports. Data were synthesised narratively, without pooling or formal risk-of-bias assessment.
Results
Preclinical evidence shows that gypenosides suppress NADPH oxidase 4 (NOX4)-derived ROS and γH2AX-marked DNA damage in endothelial cells; preserve mitochondrial respiration, membrane potential, and ATP while restraining permeability transition pore opening and cytochrome c release during I/R; and improve systemic and hepatic lipid profiles while reinforcing endogenous antioxidant defences. These actions translate into reduced infarct size, improved left-ventricular function, and attenuated atherogenesis.
Discussion
Gypenosides are promising multi-target cardioprotective candidates, positioned here within the saponin family and contrasted with ginsenosides. Clinical studies of gypenoside preparations are small and assess lipid and endothelial surrogate markers only, and no cardiovascular outcome trials exist. Extract standardisation and pharmacokinetics must be addressed before therapeutic potential can be confirmed.
Förderung
- National Science and Technology Council
Zitieren
APA
Muthanna, A., Lee, Y. Z., Voon, F., d’Arqom, A., Tham, C., Ho, Y., & Lee, M. T. (2026). Potential cardioprotective effects of gypenosides: a review on preclinical studies targeting the ROS-mitochondria-lipid axis in atherosclerosis and ischaemia-reperfusion injury. Pharmacological Research - Modern Chinese Medicine, 100901. https://doi.org/10.1016/j.prmcm.2026.100901
Vancouver
Muthanna A, Lee YZ, Voon F, d’Arqom A, Tham C, Ho Y, et al. Potential cardioprotective effects of gypenosides: a review on preclinical studies targeting the ROS-mitochondria-lipid axis in atherosclerosis and ischaemia-reperfusion injury. Pharmacological Research - Modern Chinese Medicine. 2026:100901. doi:10.1016/j.prmcm.2026.100901
BibTeX
@article{Muthanna2026,
author = {Muthanna, AbdulRahman and Lee, Yu Zhao and Voon, Fui-Ling and d’Arqom, Annette and Tham, Chau-Ling and Ho, Yu-Cheng and Lee, Ming Tatt},
title = {Potential cardioprotective effects of gypenosides: a review on preclinical studies targeting the ROS-mitochondria-lipid axis in atherosclerosis and ischaemia-reperfusion injury},
journal = {Pharmacological Research - Modern Chinese Medicine},
year = {2026},
pages = {100901},
doi = {10.1016/j.prmcm.2026.100901}
}
EUVIMED